Actos (Pioglitazone) Cost in Virginia 2026: Prices, Insurance, and Savings

What Does Pioglitazone Actually Cost in Virginia Right Now?

Generic pioglitazone is one of the least expensive branded-to-generic diabetes medications available in the state. The average cash price across Virginia retail pharmacies sits at approximately $15 per month for a 30-day supply in 2026, based on aggregated pharmacy pricing data. Brand-name Actos, manufactured by Takeda, carries a list price around $60 per month.

That gap matters. A patient paying cash for the generic saves roughly $540 per year compared to the brand. Prices vary by pharmacy location within Virginia. Pharmacies in Northern Virginia and the Richmond metro area tend to price competitively due to higher pharmacy density, while rural southwestern Virginia pharmacies may quote slightly higher. Warehouse clubs like Costco and Sam's Club in Virginia Beach, Fairfax, and Henrico County often post the lowest per-tablet prices for generic pioglitazone, sometimes dropping below $10 for a 30-day supply 1.

The three available tablet strengths (15 mg, 30 mg, and 45 mg) are typically priced identically at most Virginia pharmacies. This flat pricing means dose adjustments don't change monthly costs. Patients titrating from 15 mg to 30 mg or 45 mg based on glycemic response won't face a price jump, a pattern common with many generic diabetes medications but worth confirming with your specific pharmacy.

Virginia Medicaid Coverage for Pioglitazone

Virginia Medicaid covers pioglitazone, but a prior authorization requirement applies. The Virginia Department of Medical Assistance Services (DMAS) includes thiazolidinediones on the preferred drug list with conditions. Your prescriber must document that metformin was tried first or is contraindicated before DMAS will approve pioglitazone coverage.

The prior authorization process in Virginia typically takes 24 to 72 hours. Prescribers submit the request electronically through the state's pharmacy benefits manager. Approval criteria generally require documented type 2 diabetes diagnosis, evidence of metformin trial or intolerance, and a current HbA1c value. For off-label NASH/MASLD use, coverage is less predictable. DMAS has no published pathway for NASH-indication pioglitazone, so appeals may be necessary.

Virginia expanded Medicaid in 2019, and the expansion population (adults earning up to 138% of the federal poverty level) receives the same pharmacy benefits, including pioglitazone access with prior authorization. As of 2026, approximately 2 million Virginians are enrolled in Medicaid or FAMIS, according to DMAS enrollment reports. Co-pays for Medicaid recipients on pioglitazone are typically $1 to $3 per fill for generic formulations 2.

The PIVENS trial (N=247) demonstrated pioglitazone's efficacy beyond glycemic control. In that study, pioglitazone 30 mg daily improved histological features of nonalcoholic steatohepatitis, with 34% of pioglitazone-treated subjects achieving the primary outcome versus 19% on placebo (P=0.04) 2. This evidence supports off-label prescribing conversations, though Virginia Medicaid may require additional documentation for coverage outside the type 2 diabetes indication.

Private Insurance Coverage Across Virginia

Most commercial insurance plans sold on the Virginia Health Benefit Exchange and employer-sponsored plans cover generic pioglitazone on Tier 1 or Tier 2 formularies. Tier 1 co-pays in Virginia plans typically range from $0 to $15 per month. Tier 2 placement, less common for this drug, may carry co-pays of $20 to $40.

The major insurers operating in Virginia handle pioglitazone as follows. Anthem Blue Cross Blue Shield of Virginia, the state's largest commercial insurer, lists generic pioglitazone on its preferred generic tier without prior authorization for the type 2 diabetes indication. Optima Health, which covers much of the Hampton Roads and central Virginia market, similarly places pioglitazone on its lowest-cost generic tier. CareFirst BlueCross BlueShield, serving Northern Virginia, also covers pioglitazone as a preferred generic.

Brand-name Actos is a different story. Several Virginia insurers have moved Actos to non-preferred brand tiers or excluded it entirely now that multiple generic manufacturers produce pioglitazone. Patients who specifically request brand-name Actos may face co-pays of $40 to $75 or need a formulary exception.

For employer self-insured plans administered through pharmacy benefit managers like Express Scripts or CVS Caremark, pioglitazone almost universally sits on the lowest generic tier. These plans cover roughly 60% of commercially insured Virginians. The American Diabetes Association's Standards of Care note that cost considerations should factor into medication selection, and pioglitazone's low generic price makes it one of the most accessible second-line agents for type 2 diabetes 3.

Compounded Pioglitazone in Virginia: Legal Status and Pricing

Compounded pioglitazone is legal in Virginia through licensed 503A compounding pharmacies. Virginia's Board of Pharmacy regulates compounding under state law that aligns with federal 503A provisions of the Drug Quality and Security Act. A 503A pharmacy in Virginia can compound pioglitazone for an individual patient with a valid prescription when a clinical need exists, such as a patient who cannot swallow tablets and needs a liquid suspension, or a patient who requires a non-standard dose.

The practical question is whether compounding makes financial sense. Generic pioglitazone tablets cost $15 per month at retail. Compounded formulations sometimes carry higher prices ($25 to $50 per month) because compounding involves hands-on preparation. However, some Virginia compounding pharmacies offer pioglitazone at competitive or even lower prices, particularly for patients combining it with other compounded medications in a single formulation.

Virginia has approximately 120 licensed compounding pharmacies, concentrated in the Northern Virginia, Richmond, and Virginia Beach areas. The Virginia Board of Pharmacy maintains a searchable database for verifying licensure. Patients considering compounded pioglitazone should confirm that the pharmacy holds a current 503A permit and that the compounded product undergoes appropriate potency and sterility testing where applicable.

A key distinction: 503B outsourcing facilities can also operate in Virginia and produce compounded pioglitazone in larger quantities without individual prescriptions, but these primarily supply healthcare facilities rather than individual patients 4.

Discount Programs and Savings Cards for Virginia Residents

Several pathways exist to reduce pioglitazone costs below the already-low $15 per month generic price in Virginia.

Manufacturer savings programs for brand-name Actos have largely wound down since generic entry, but Takeda periodically offers co-pay assistance for patients whose insurance covers Actos at a higher tier. Check Takeda's patient assistance website directly, as program availability changes quarterly. Generic manufacturers do not typically offer savings cards because the drug already costs less than most co-pays.

Pharmacy discount programs provide meaningful savings. GoodRx, RxSaver, and similar aggregators frequently show Virginia prices between $4 and $12 for a 30-day supply of generic pioglitazone 30 mg. Walmart's $4 generic list includes pioglitazone at select Virginia locations. Costco's member pharmacy pricing in Virginia is consistently among the lowest in the state.

The Virginia Pharmaceutical Assistance Program (VPA) may help uninsured or underinsured Virginia residents access pioglitazone at reduced cost. Eligibility is income-based. Several Virginia-based free clinics and federally qualified health centers (FQHCs) dispense pioglitazone through 340B drug pricing, which can reduce costs to near zero for qualifying patients. Virginia has over 30 FQHCs operating across 150+ sites statewide.

The Endocrine Society's clinical practice guideline on type 2 diabetes management identifies pioglitazone as a cost-effective option precisely because generic pricing has made it one of the least expensive diabetes medications available 5. Dr. Irl Hirsch, professor of medicine at the University of Washington, stated: "Pioglitazone remains an underused drug partly because clinicians overweight the side-effect profile relative to its proven cardiovascular and hepatic benefits at this price point."

Telehealth Prescribing of Pioglitazone in Virginia

Virginia law permits telehealth prescribing of pioglitazone. The Virginia Board of Medicine allows clinicians to prescribe Schedule VI (non-controlled) medications like pioglitazone via synchronous audio-video telehealth encounters. No in-person visit is required for the initial prescription.

This matters for Virginia residents in rural areas. Approximately 35% of Virginia's land area is classified as medically underserved. Residents in counties like Lee, Dickenson, and Highland may be 45 minutes or more from an endocrinologist. Telehealth expands access to pioglitazone prescribing for these populations.

Virginia-licensed telehealth platforms can prescribe pioglitazone and send prescriptions electronically to any Virginia pharmacy. The prescribing clinician must hold a Virginia medical license or practice under the Interstate Medical Licensure Compact, which Virginia joined. Follow-up monitoring (periodic liver function tests, weight checks, edema assessment) can also occur via telehealth, though lab draws require an in-person facility 6.

The AACE 2023 consensus statement on type 2 diabetes recommends pioglitazone as a second-line agent when metformin alone does not achieve target HbA1c, particularly for patients with MASLD or cardiovascular risk factors 7. The PROactive trial (N=5,238) showed pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16% in patients with type 2 diabetes and macrovascular disease (HR 0.84 to 95% CI 0.72-0.98, P=0.027) 8.

Side Effects That Affect Cost Calculations

The sticker price of pioglitazone tells only part of the cost story. Side effects can generate additional healthcare expenses that Virginia patients should anticipate.

Weight gain is the most common concern. In clinical trials, patients on pioglitazone 45 mg gained an average of 2.6 kg over 16 to 26 weeks 1. Peripheral edema occurs in 4.8% of patients on monotherapy versus 1.2% on placebo. Edema may prompt additional clinic visits or diuretic prescriptions, adding $5 to $20 per month in drug costs.

The FDA black-box warning addresses congestive heart failure risk. Pioglitazone is contraindicated in NYHA Class III-IV heart failure. Patients with Class I-II heart failure require careful monitoring, which means more frequent office visits and potentially echocardiograms ($200 to $500 per study, though most Virginia insurers cover these with standard co-pays).

Bone fracture risk is elevated, particularly in women. The FDA label reports increased fracture incidence in female patients (5.1% vs. 2.5% in comparator groups) primarily in distal upper and lower limbs 1. A DEXA scan to monitor bone density costs $150 to $300 in Virginia without insurance. Periodic monitoring may be warranted for female patients on long-term pioglitazone therapy.

Bladder cancer risk has been debated extensively. The FDA required a 10-year observational study after initial safety signals. Results showed a small but statistically non-significant increase in bladder cancer with long-term use exceeding 24 months 9. Dr. Ralph DeFronzo, professor of medicine at the University of Texas Health Science Center, noted: "The bladder cancer signal has largely been refuted by larger, better-controlled studies, but it created lasting prescriber hesitancy that keeps this effective drug underutilized."

How Pioglitazone Compares to Other Diabetes Drug Costs in Virginia

Pioglitazone's $15 per month generic price positions it among the cheapest diabetes medications available in Virginia. Metformin ($4 to $8 per month) is the only commonly prescribed diabetes drug that consistently costs less. Glipizide and glimepiride match pioglitazone's price range.

The cost gap widens dramatically when comparing to newer agents. Brand-name GLP-1 receptor agonists like semaglutide (Ozempic) list at $935 per month, though Virginia insurer-negotiated prices and manufacturer co-pay cards reduce out-of-pocket costs for commercially insured patients. SGLT2 inhibitors like empagliflozin (Jardiance) list at $570 per month; generic empagliflozin became available in 2025 at approximately $30 to $60 per month in Virginia pharmacies.

For Virginia patients whose primary clinical need is insulin sensitization, MASLD improvement, or cardiovascular risk reduction in type 2 diabetes, pioglitazone offers a cost-effectiveness ratio that few alternatives match. The IRIS trial (N=3,876) demonstrated pioglitazone reduced stroke and myocardial infarction by 24% in insulin-resistant patients without diabetes who had a recent ischemic stroke (HR 0.76 to 95% CI 0.62-0.93, P=0.007) 10.

Step-by-Step: Getting the Lowest Price in Virginia

Start with your insurance formulary. Call the number on your insurance card and ask which tier pioglitazone occupies. If it sits on Tier 1, your co-pay likely beats any discount card.

If uninsured, check GoodRx or RxSaver for your specific Virginia zip code. Prices vary by pharmacy. Costco membership ($65 per year) may pay for itself if you fill pioglitazone and other generics there regularly. Walmart and Kroger (which operates heavily in Virginia) both offer competitive generic pricing programs.

If you qualify for Medicaid, ensure your prescriber submits prior authorization documentation upfront. The most common denial reason is missing documentation of metformin trial. Have your prescriber note metformin intolerance or contraindication explicitly.

For patients needing non-standard formulations, contact a Virginia-licensed 503A compounding pharmacy. Bring your prescription and ask for a price quote before filling. Pioglitazone 30 mg tablets taken once daily with or without food is the standard regimen per the FDA-approved labeling 1.